The Japanese journal of surgery

, Volume 15, Issue 4, pp 279–284 | Cite as

In vitro chemosensitivity tests on human tumor xenografts by clonogenic assay: the combined use of mitomycin C with α-interferon or γ-interferon

  • Naoki Hirabayashi
  • Ken Yoshinaka
  • Yoshihiro Nosoh
  • Tetsuya Toge
  • Minoru Niimoto
  • Takao Hattori
  • Takeshi Ohkita
Original Articles


Using the human tumor clonogenic assay technique, the effects of Mitomycin C plus either α-interferon or γ-interferon were studied against five human tumor xenografts serially transplanted into nude mice (three gastric and two colon cancers). When the survival fraction found with the drug combination was smaller than the multiplication of survival fractions with either drug alone, the combined effect was defined as synergism. Similarly, antagonistic effect was defined when the survival fraction of drug combination was larger than the larger one observed in either interferon or Mitomycin C alone. Four out of five human tumor xenografts (three gastric and one colon cancers) showed synergistic effects in combination of α-interferon with Mitomycin C. Though two gastric cancer xenografts exhibited synergistic effects in combination of γ-interferon with Mitomycin C, antagonistic effects, which was not found in combination of α-interferon with Mitomycin C, were observed in one gastric cancer and one colon cancer xenografts.

Key words

α-interferon γ-interferon clonogenic assay drug combination 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Taylor-Papadimitriou J, Balkwill FR. Implications for clinical application of new developments in interferon research. Biochemica et Biophysica Acta 1982; 695: 49–67.Google Scholar
  2. 2.
    Neidhart JA, Gagen, MM, Young D, Tuttle R, Melink TJ, Ziccarrelli A, Kisner, D. Interferon-α therapy of renal cancer. Cancer Res 1984; 44: 4140–4143.PubMedGoogle Scholar
  3. 3.
    Kimura K. A cooperative phase I–II study of HLBI in patients with malignant tumors. Gann to Kagakuryoho (Jpn J Cancer Chemother) 1984; 11: 1324–1331. (English Abst.)Google Scholar
  4. 4.
    Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197: 461–463.PubMedGoogle Scholar
  5. 5.
    Hamburger AW, Salmon SE, Kim MB, Trent JM, Soehnlen BJ, Alberts DS, Schmidt HJ. Direct cloning of human ovarian carcinoma cells in agar. Cancer Res 1978; 38: 3438–3444.PubMedGoogle Scholar
  6. 6.
    Valeriote F, Lin S. Synergistic interaction of anticancer agents: A cellular perspective. Cancer Chemotherapy Reports 1975; 59: 895–900.Google Scholar
  7. 7.
    Momparler RL.In vitro systems for evaluation of combination chemotherapy. Pharmac Ther 1980; 8: 21–35.CrossRefGoogle Scholar
  8. 8.
    Chirigos MA, Pearson JW. Care of murine leukemia with drug and interferon treatment. J Natl Cancer Inst 1973; 51: 1367–1368.PubMedGoogle Scholar
  9. 9.
    Gresser I, Maury C, Tovey M. Efficacy of combined interferon cyclophosphamide therapy after diagnosis lymphoma in AKR mice. Eur J Cancer 1978; 14: 97–99.PubMedGoogle Scholar
  10. 10.
    Balkwill FR, Moodie EM. Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 1984; 44: 904–908.PubMedGoogle Scholar
  11. 11.
    Schabel FM, Laster WR, Trader MW, Mowshowit SL, Smith GD. Anticancer activity of mouse interferon alone and in combination with cis-dichlorodiammineplatinum II or mitomycin-C against leukemia P388 in mice. Proc Am Ass Cancer Res 1982; p 190.Google Scholar
  12. 12.
    Noshoh Y, Yoshinaka K, Yamaguchi M, Tani T, Toge T, Niimoto M, Hattori T. Increased cytotoxic effect of various anticancer drugs by α-interferon (HLBI) on human xenografts in nude mice. Gann to Kagakuryoho (Jpn J Cancer Chemother) 1984; 11: 1623–1628. (English Abst.)Google Scholar
  13. 13.
    Brostrom LA. The combined effect of interferon and methotrexate on human osteosarcoma and lymphoma cell lines. Cancer Lett 1980; 10: 83–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Aapro MS, Albert DS, Salmon SE. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 1983; 10: 161–166.PubMedCrossRefGoogle Scholar
  15. 15.
    Oku T, Imanishi J, Kishida T. Assessment of antitumor cell effect of human leukocyte interferon in combination with anticancer agents by a convenient assay system in monolayer cell culture. Gann 1982; 73: 667–674.PubMedGoogle Scholar
  16. 16.
    Leandersson T, Lundgren E. Cell growth regulation during density inhibition and interferon treatment. Exp Cell Res 1982; 138: 167–174.PubMedCrossRefGoogle Scholar
  17. 17.
    Roos G, Leanderson T, Lundgren E. Interferon-induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells. Cancer Res 1984; 44: 2358–2362.PubMedGoogle Scholar
  18. 18.
    Tyring S, Klimpel GR, Fleischmann WR, Baron S. Direct cytolysis by partially-purified preparations of immune interferon. Int J Cancer 1982; 30: 59–64.PubMedGoogle Scholar
  19. 19.
    Blalock JE, Georgiades JA, Langford MP, Johnson HM. Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon. Cellular Immunol 1980; 49: 390–394.CrossRefGoogle Scholar
  20. 20.
    Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R. Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 1981; 70: 1027–1032.CrossRefGoogle Scholar

Copyright information

© The Japan Surgical Society 1985

Authors and Affiliations

  • Naoki Hirabayashi
    • 1
  • Ken Yoshinaka
    • 1
  • Yoshihiro Nosoh
    • 1
  • Tetsuya Toge
    • 1
  • Minoru Niimoto
    • 1
  • Takao Hattori
    • 1
  • Takeshi Ohkita
    • 2
  1. 1.Department of Surgery, Research Institute for Nuclear Medicine and BiologyHiroshima UniversityHiroshimaJapan
  2. 2.Department of Hematology, Research Institute for Nuclear Medicine and BiologyHiroshima UniversityHiroshimaJapan

Personalised recommendations